3-Amino-4-[(3-hydroxy-4-methoxyphenyl)diazenyl]-1,4-dihydropyrazol-5-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-Amino-4-[(3-hydroxy-4-methoxyphenyl)diazenyl]-1,4-dihydropyrazol-5-one
• 化学式: C₁₀H₁₁N₅O₃
• 分子量: 249.23
• InChiKey: AAFLKOZSCJNAJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Pyrazole compounds
  申请人：——

  公开号：US20020042501A1

  公开（公告）日：2002-04-11

  Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供了药物组合物和化合物。本发明的化合物具有抗增殖活性，并可能促进缺乏正常细胞周期和死亡调控的细胞凋亡。在本发明的一个实施例中，提供了与生理上可接受的载体结合的化合物配方。这些药物配方在治疗高增殖性疾病方面很有用，这些疾病包括肿瘤生长、淋巴增殖性疾病、血管生成等。本发明的化合物是取代的吡唑和吡唑烯。
• PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY
  申请人：Kinetek Pharmaceuticals, Inc.

  公开号：EP1276723A2

  公开（公告）日：2003-01-22
• US6214813B1
  申请人：——

  公开号：US6214813B1

  公开（公告）日：2001-04-10
• US6436915B1
  申请人：——

  公开号：US6436915B1

  公开（公告）日：2002-08-20
• [EN] PYRAZOLE COMPOUNDS<br/>[FR] COMPOSES DE PYRAZOLE
  申请人：KINETEK PHARMACEUTICALS INC

  公开号：WO2001077080A2

  公开（公告）日：2001-10-18

  Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.